drugset / Trial / NCT04067102
Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC
Withdrawn
Hebei Medical University Fourth Hospital
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of P nab-paclitaxel combined with carboplatin versus paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide in the neoadjuvant treatment of triple negative breast cancer.
Timeline
- Start
- 2019-05-10
- Primary completion
- 2021-05
- Completion
- 2026-05
Outcome
Outcome not reported
Stopped (Enrollment): “No patients recruited”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 260 mg/m2 | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Epirubicin | Small molecule | — | — |